iA Global Asset Management Inc. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

iA Global Asset Management Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 199,882 shares of the biopharmaceutical company’s stock after buying an additional 24,815 shares during the period. iA Global Asset Management Inc.’s holdings in Gilead Sciences were worth $18,463,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Teacher Retirement System of Texas increased its holdings in shares of Gilead Sciences by 32.1% in the 4th quarter. Teacher Retirement System of Texas now owns 442,579 shares of the biopharmaceutical company’s stock worth $40,881,000 after buying an additional 107,566 shares during the last quarter. Grey Fox Wealth Advisors LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $211,000. Generali Investments Management Co LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $1,095,000. Harvest Fund Management Co. Ltd increased its holdings in shares of Gilead Sciences by 41.0% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 80,889 shares of the biopharmaceutical company’s stock worth $7,375,000 after buying an additional 23,512 shares during the last quarter. Finally, Koss Olinger Consulting LLC increased its holdings in shares of Gilead Sciences by 21.6% in the 4th quarter. Koss Olinger Consulting LLC now owns 38,249 shares of the biopharmaceutical company’s stock worth $3,533,000 after buying an additional 6,782 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 2.5 %

NASDAQ:GILD opened at $107.51 on Thursday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The firm has a 50 day moving average of $103.00 and a 200 day moving average of $93.47. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $133.89 billion, a price-to-earnings ratio of 290.57, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.94%. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Morgan Stanley boosted their target price on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday, March 11th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Oppenheimer upped their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.